Brief: BeOne Medicines And Revolution Medicines Announce Clinical Development And Regional Commercialization Collaboration
10/08/2026 11:05
BRIEF-BeOne Medicines And Revolution Medicines Announce Clinical Development And Regional Commercialization Collaboration Aug 10 (Reuters) - BeOne Medicines AG 688235.SS:
BEONE MEDICINES AND REVOLUTION MEDICINES ANNOUNCE CLINICAL DEVELOPMENT AND REGIONAL COMMERCIALIZATION COLLABORATION
BEONE MEDICINES - RECEIVES EXCLUSIVE RIGHTS TO FOUR REVOLUTION MEDICINES ASSETS IN SELECT ASIAN MARKETS
BEONE MEDICINES - TO FUND AND CONDUCT GLOBAL PHASE 3 STUDY FOR RAS(ON) INHIBITOR
BEONE MEDICINES - REVOLUTION MEDICINES ELIGIBLE FOR MILESTONE PAYMENTS AND TIERED ROYALTIES IN PARTNERED REGION
Source text: ID:nBw5ppjj7a
Further company coverage: 688235.SS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Revolution Medicines
See all newsAnalysis: Revolution Medicines' Europe efforts signal solo launch ambitions for cancer drug
Brief: CHMP Recommends Granting Marketing Authorisation For Rasonque For Metastatic Pancreatic Cancer In EU
Revolution Medicines wins EU committee backing for pancreatic cancer treatment (updated)
EMA recommends approval of Revolution's pancreatic cancer drug
Revolution Medicines falls on pancreatic cancer drug data concerns